Merck, GSK, J&J Broaden Strategic LP Relationships, External Discovery Initiatives

In the latest examples of biotech VCs and Big Pharma joining forces to prospect for products, Index Ventures announced in March that it had raised a new €150 million life sciences venture fund, Index Life VI, and said that GSK and J&J had committed a combined 50% of the fund’s total capital. Three weeks later Merck said it added early-stage life science venture firm Flagship Ventures to the roster of venture funds it has joined as a limited partner. The investments signal continued interest in externalizing discovery and early-stage development by industry and feature new steps in an ongoing dance between industry’s largest players and the venture investors at the forefront of building biotechs and identifying promising assets.

In the latest examples of biotech venture capitalists and Big Pharma joining forces to prospect for products, Index Ventures announced March 21 that it had raised a new €150 million life sciences venture fund, Index Life VI, and said that GlaxoSmithKline PLC and Johnson & Johnson had committed a combined 50% of the fund’s total capital. Three weeks later on April 10, Merck & Co. Inc. said it added early stage life science venture firm Flagship Ventures to the roster of venture funds it has joined as a limited partner.

The investments signal continued interest in externalizing discovery and early stage development by industry and feature new steps in an...

More from Business Strategy

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.